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Abstract
Background: Acute kidney injury is frequently observed at the intensive care unit, after surgery, and after toxic
drug administration. A rise in serum creatinine and a fall in urine output are consequences of much earlier injury to
the most sensitive part of tubular cells located at the proximal tubule. The aim of the present study was to investigate
the course of two cell-cycle arrest urinary biomarkers compared to serum creatinine in four clinical settings: ischemic
reperfusion injury, cardiac failure, severe acute kidney injury, and chemotherapy-induced kidney injury.
Methods: A recently developed bedside test known as NephroCheck measures two urinary parameters: insulin-like
growth factor binding protein 7 (IGFBP7) and tissue inhibitor of metalloproteinase-2 (TIMP-2). The test is based on a
sandwich immunoassay technique. The final test output, labeled AKIRisk, is shown as a numeric result.
Results: This report revealed that [IGFBP7] · [TIMP-2] in urine rise rapidly prior to any change in serum creatinine. A
unique feature of all four clinical settings is that a rapid decline predicts the recovery of kidney function. Besides, a
subclinical kidney injury might be detected by the test.
Conclusion: This bedside test detects biomarkers of renal injury. A rapid decline in AKIRisk was associated with the
restoration of kidney function, whereas a prolonged high AKIRisk score was associated with end-stage renal disease.
However, the dynamics seem to differ, depending on the cause and the extent of injury. Further studies will be
needed to clarify the issue.
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Background
Acute kidney injury (AKI) is common in patients at the
intensive care unit and after surgery [1, 2]. Independent
of the severity of injury, the patients are subject to a
high risk of developing end-stage renal disease (ESRD)
[3, 4]. Serum creatinine (sCr) is a late marker of AKI
and is routinely determined for the assessment of kidney
function [5]. The most challenging aspect of AKI is the
absence of clinical symptoms because the trauma occurs
in individual nephrons which are not monitored or
registered by nociception. Clinical evidence is usually
obtained more than 12 h later, based on changes in sCr
and urine output [6, 7]. The diagnostic parameters re-
ported thus far include neutrophil gelatinase-associated
lipocalin (NGAL) [8], kidney injury molecule 1 (Kim-1)
[9], cystatin C (Cys C), liver fatty acid binding protein
(L-FABP), and interleukin 18 (IL 18) [10]. The usefulness
of these markers in predicting AKI has been reviewed in
detail [11, 12].
A novel test method, known as NephroCheck™,
measures two small tubular cell-derived molecules,
[IGFBP7] · [TIMP-2]. According to recently published
data, this test possesses the highest sensitivity for detect-
ing AKI at an early stage [13, 14]. Given the short test
procedure of twenty minutes from urine collection to
the outcome, it can be used at any clinical ward, out-
patient clinic, or intensive care unit [13, 15].
IGFBP7 and TIMP-2 are markers of cell cycle arrest
and possibly apoptosis, inflammation, and tubular cell
repair [13, 16]. These cell biological conditions appear to
be most relevant in the development of tubular cell
injury, when the loss of cell polarity, brush border
derangement, and cell sloughing might occur [17, 18].
Such injury may induce cellular repair mechanisms, but
may also deflect the organism from normal repair
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towards maladaptive repair by reducing perfusion, caus-
ing inflammation and subsequent fibrosis. This may then
lead to chronic kidney disease (CKD), which further pre-
disposes the individual to recurrent acute kidney injury
[17–19]. Such pathological conditions have been de-
tected in sepsis-induced lesions in humans [20], and
ischemic reperfusion injury (IRI) studies in animal
models [21]. The pathology caused by antibiotics, con-
trast media or specific chemotherapeutic agents is
mainly observed in tubular cells [6]. Depending on the
severity of injury, both apoptosis and necrosis of tubular
cells have been reported as part of the cisplatin toxicity
profile, which includes direct DNA damage, inflamma-
tion, and the activation of specific pathways [22]. This is
a limitation of cisplatin, which is known to be a highly
effective chemotherapeutic agent for the treatment of
cancer [23].
We evaluated the applicability of the test method in
selected patients at our nephrology inpatient ward who
were deemed susceptible to AKI, including those with
preexisting CKD. The following entities were included:
kidney injury following IRI during kidney transplantation
(TX), AKI due to cardiac failure, severe AKI, and
chemotherapy-induced kidney injury related to cisplatin.
The course of [IGFBP7] · [TIMP-2] were monitored in
comparison to serum creatinine.
Methods
Sixty-nine consecutive patients were tested at the
nephrology inpatient ward (n = 52) and the oncology
ward (n = 17) of the University Hospital of Vienna from
2013 to 2014. Inclusion criteria were the following: age
over 18 years, clinical signs of comorbidities constituting
a high risk of AKI or evident AKI. Only patients admit-
ted to the intensive care unit and the nephrology in-
patient clinic were selected for testing. These included
kidney transplant recipients for the evaluation of ische-
mic reperfusion injury. Preexistent chronic kidney dis-
ease was no exclusion criterion in the nephrology group.
Inclusion criteria in the cisplatin group were age
higher than 18 years, no history of CKD, and the initi-
ation of chemotherapy based on cisplatin. Written and
oral informed consent to the study and publication of
the results was obtained from all patients. The investiga-
tion was approved by the ethics committee of the Medical
University of Vienna (approval number 1598/2013). The
patients’ clinical data, demographics, medical history,
medication and laboratory data were obtained from their
medical files and the databases of the hospital. Representa-
tive patients (oncology inpatients, inpatients with more
than four data points, and hospitalization for more than
4 days) were selected. Twelve patients were chosen for the
report; a further four cases have been described in the
supplement (Additional file 1: Table A).
NephroCheck measurements were performed every
24- to 48-h and were discontinued when either sCr
reached baseline values or the NephroCheck score fell
below 0.3. Endpoints of measurement were patient
discharge, an anuric status, and outcomes such as renal
replacement therapy (RRT) or death.
Analyses of urine samples for the biomarker combin-
ation of [IGFBP7] · [TIMP-2] were performed with
NephroCheck™, a tool designed by a California-based
biotechnology company (Astute Medical, San Diego,
CA, USA). The Astute140TM meter is a device based on a
fluorescence labeling technique, which detects fluorescent
signals from the immunoassay and calculates concentra-
tions of IGFBP7 and TIMP-2 from the inserted cartridge.
The device converts the measured signals into a single
number, defining the relative risk of the patient developing
AKI. The final result, known as the AKIRisk score, is
obtained within 20 min. Quality controls were performed
as recommended and provided by the manufacturer.
Urine samples were tested immediately for all patients
at the nephrology department. For those at the oncology
department, a maximum delay of 2 h occurred be-
tween collection and testing. In case immediate ana-
lysis was not possible, the samples were frozen at −20 °C
after centrifugation and stored. Frozen samples were
thawed and warmed to room temperature, and the
NephroCheck™ test was performed immediately.
Results
Owing to the wide range of clinical settings, the patients’
data are presented in four groups consisting of individ-
ual case reports and graphic demonstrations in numeric
order (#1- #12) depicted in Fig. 1. Demographic data
and patient characteristics, including relevant informa-
tion about the stage of AKI, peak AKIRisk and outcome,
are shown in Table 1. Further four patients are shown in
the supplements (Additional file 1: Table A, Additional
file 2, Additional file 3: Figure A). Demographic data of
the entire cohort, including AKI stages and the highest
AKIRisk during the observation period are shown in
the supplements (Additional file 4: Table B).
Cadaver kidney recipients
Patient #1: A 66-year-old man received a cadaver kidney
organ with a cold ischemia time of 12 h. After transplant-
ation the patient was observed briefly at the intermediate
intensive care unit and then transferred to the internal
ward, where urine output monitoring was started. The pa-
tient had been anuric for the preceding 6 months, requir-
ing constant hemodialysis (HD). Oliguria was observed
from day 1 to 4, followed by a phase of polyuria starting
on day 5 with a decrease in sCr. Interestingly, the AKIRisk
score on the NephroCheck™ test was high (1.6) when the
patient’s initial urine output started, and fell rapidly to
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levels below 0.06 prior to the phase of polyuria. Two
weeks after transplantation the patient needed a transplant
nephrectomy due to rupture of the renal artery.
Patient #2: A 38-year-old man, oliguric and on dialysis
for the last 2 years, received a cadaver kidney organ
from a 15-year-old female non-heart-beating donor.
Fig. 1 Dynamics of AKIRisk and serum creatinine. Time course (X- axis) of [IGFBP7] · [TIMP-2] labelled as AKIRisk on the left Y-axis (gray rectangles)
and serum creatinine on the right Y-axis (black circles) in 12 patients within 4 different clinical settings. Case reports: kidney transplant recipients
#1-#3; cardiac failure #4-#7; severe AKI #8-#9; chemotherapy induced kidney injury #10-#12. On the X-axis for the chemotherapy cohort the first
digit represents the number of cycle, while the second digit is indicating the day of chemotherapy. sCr, serum creatinine in mg/dl; KTX, kidney
transplantation; HD, hemodialysis; LTX, liver transplantation
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After transplantation the patient was observed briefly at
the surgery ward and then transferred to the internal
ward (day 1) for further monitoring. The patient was oli-
guric to anuric during day 1–16. Donor organ perfusion
and urinary tract morphology were monitored on a daily
basis. Hemodialysis had to be performed three times
from day 12 to day 19 post-transplantation. The patient
needed stenting of the ureteral ostium to the bladder on
day 12, and percutaneous drainage of the transplanted
kidney pelvis. A percutaneous kidney biopsy revealed
tubular cell damage, but no signs of graft rejection.
TIMP-2 staining of tubular cells obtained from the urin-
ary sediment on day 25 is shown in the supplement
(Additional file 5: Figure B). Finally the patient was dis-
charged 40 days post-transplantation, after a long period
of gradually increasing urine volume. The AKIRisk score
was high on day 1 (1.86), but could not be evaluated
until day 20 because of bladder injury and constant blad-
der flushing with normal saline. The patient’s AKIRisk
parameters were measured from day 20 until discharge,
which decreased from 0.69 to 0.03. Urine output in-
creased, accompanied by a fall in sCr.
Patient #3: A 66-year-old male kidney transplant
patient experienced a hemorrhagic shock and lost his
transplant function, requiring dialysis on day 1 and
day 3. The patient was stabilized at the intensive care
unit and then admitted to the internal ward on day 5.
His urine output started from this time on, and
AKIRisk levels could be measured. This was followed
by a phase of polyuria and almost complete recovery
of transplant organ function to pre-accident levels.
The initially high AKIRisk of 4.7 on day 1 declined
rapidly to 0.15 much earlier than did sCr, clearly indi-
cating the restoration of transplant organ function.
Cardiac failure
Patient #4: A 69-year-old woman with a history of dia-
betic nephropathy underwent cardiac bypass surgery
during which she had to be resuscitated, but was eventu-
ally stabilized. Her kidney function deteriorated most
likely due to infection and cardiac insufficiency, which
was manifested by her decreasing urine output and ris-
ing sCr on day 3. This was paralleled by a rise in the
AKIRisk score to 8.1, which dropped on day 7 after fluid
Table 1 Characteristics of patients
ID Age Sex BSL sCr BSL GFR AKI Stage Reason AKI Peak
AKIRisk
Outcome/sCr Disease Surgeries
1 66 m 11.29 4.5 End Stage IRI 1.6 transplantectomy
dialysis (0,5 m)
CKD, HTN cadaver KTX
2 38 m 7.26 16.11 End Stage IRI 1.86 3,48 (14 m) CKD, HTN, mitral and
aortic valve regurgitation
cadaver KTX
3 66 m 1.4 56.55 stage 3 prerenal, hypotension,
shock
4.74 1,53 (19 m) CKD, KTX, AKI,
cardiomyopathy, afib
thoracotomy




5 77 m 1.66 43.14 stage 3 prerenal, shock 5.86 Death CTEPH, hyponatremia none




7 73 m 1.3 64.63 No AKI contrast media 3.12 1,26 (3 m) HTN, mitral and aortic
valve regurgitation, afib
none
8 56 f unknown unknown stage 3 acute hepatits B 73 Lost to follow up AKI, acute hepatitis B LTX
9 78 m 8.2 6.79 End Stage tubular injury
membranous GN
18 5,48 (12 m) CKD, HTX, HTN, NIDDM none
10 41 m 0.93 98.18 No AKI toxic insult 4.08 1,16 (2 m) signet ring cell carcinoma
of gaster
none
11 54 m 0.67 123.59 No AKI toxic insult 2.61 0,52 (9 m) Squamous cell carcinoma
of the esophagus, HTN
none
12 57 m 0.73 107.46 No AKI toxic insult 2.7 1,04 (13 m) hypopharyngeal carcinoma none
Demographics of the 12 patients depicted in Fig. 1 including age, sex, baseline GFR, stage of AKI, AKIRisk peak level during observation time, comorbidities and
relevant surgeries before or during the observation period. The outcome such as follow-up creatinine levels are provided, with the months of follow-up presented
in brackets. BSL sCr baseline serum creatinine in mg/dl, GFR glomerular filtration rate in ml/min, AKI acute kidney injury, sCr serum creatinine, IRI ischemia reperfusion
injury, GN glomerulonephritis, CKD chronic kidney disease, HTN hypertension, KTX kidney transplantation, CHD coronary heart disease, NIDDM non-insulin dependent
diabetes mellitus, CTEPH chronic thromboembolic pulmonary hypertension, afib atrial fibrillation, IDDM insulin dependent diabetes mellitus, HTX heart transplantation,
CPR cardiopulmonary resuscitation, CABG coronary artery bypass graft surgery, LTX liver transplantation
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substitution. SCr also fell with some delay, urine output
increased, and AKIRisk reduced 2 days earlier to 0.5.
Interestingly, the patient’s AKIRisk levels lagged behind
the sCr increase.
Patient #5: A 77-year-old man suffered from pulmon-
ary hypertension and failure of the right ventricle with
pre-admission CKD. He also had hyponatremia and se-
vere dyspnea. His symptoms worsened and his kidney
function deteriorated, showing an elevated AKIRisk
score of 5.8 on day 2. Urine flow could be reinstituted
by hydration. The patient’s blood pressure rose along
with renal perfusion, resulting in a marked reduction of
his AKIRisk score to below 0.3. However, sCr gradually
increased and the AKIRisk score rose to 5.86 on day 5,
culminating in anuria, a fatal cardiac condition, and
death on day 6.
Patient #6: A 70-year-old woman with morbid obesity
was admitted to the hospital because of dyspnea and
symptoms of cardiovascular disease. She had undergone
cardiac bypass surgery 5 years earlier. After a coronary
catheter intervention, 70 ml of contrast medium was ad-
ministered. The patient developed atrial fibrillation and
severe dyspnea the next day. This condition was associ-
ated with a rise in sCr to 6.2 mg/dl on day 1. After RRT
the patient’s condition improved and her sinus rhythm
was reinstituted. Her kidney function improved, as
reflected by a fall in sCr as well as the AKIRisk score.
Patient #7: A 73-year-old man was admitted to the
hospital for coronary catheterization prior to surgery be-
cause of severe aortic valve regurgitation and mitral
valve regurgitation. He received a contrast medium on
day 1 and day 2 for performing a computed tomography.
For his pre-existing CKD the patient received moderate
quantities of fluid pre- and post-intervention. Monitor-
ing of urine output and sCr revealed an increase in sCr
four days after initial contrast application, from 1.25 to
1.56. His AKIRisk score increased the day after the first
contrast application to 1.7, and showed peak levels at
12 h after the second contrast application to 3.12, which
then declined 2 days later to 1.64; the patient’s sCr fell
with a 24-h delay compared to his AKIRisk score. The
measurements were discontinued because the patient
was discharged from the hospital.
Severe renal failure
Patient #8: A 56-year-old woman was admitted to the
hospital because of acute hepatitis due to hepatitis B
virus infection. Her urine output was observed for 8 h,
followed by a phase of anuria. Her AKIRisk score at the
time of admission was notably high at 73; 16 h later it
dropped to 62. The next day she fell into a hepatic coma
and HD had to be instituted on day 3. Due to her deterior-
ating liver function and clinical condition, liver transplant-
ation was performed on day 8. The patient recovered
subsequently, but was unable to regain her kidney func-
tion and needed RRT until her discharge on day 44.
Patient #9: A 78-year-old patient presented with
deteriorating renal function and elevated levels of C-
reactive protein, which did not change even after anti-
biotic treatment. No therapeutic response was achieved
despite adaptation of the antibiotic regimen for more
than 2 months. A kidney biopsy showed granulocyte in-
filtration in the interstitial tissue, signs of tubular lesions,
and the presence of granulocytes in the small capillaries
of the glomeruli. Finally RRT had to be instituted after
2 months of hospital care, and could not be discontin-
ued. This type of kidney disease was the sole patho-
logical condition accompanied by a high AKIRisk score
(peak 18), throughout the observation period.
Chemotherapy-induced kidney injury
The following three case reports concern patients under-
going chemotherapy based on cisplatin. The DCF
regimen, consisting of docetaxel, cisplatin and 5-
fluorouracil, was administered in the following doses:
docetaxel 75 mg/m2 day1, cisplatin 75 mg/m2 day1 and
5-fluorouracil 750 mg/m2/24 h by continuous infusion
on days 1–5. About 3000 ml of fluid substitution was
given along with each cisplatin administration.
Patient #10: A 41-year-old patient, initially diagnosed
with gastric cancer, showed a significant rise in AKIRisk
levels to 4 after the first administration of cisplatin dur-
ing the first cycle on day 2 of the first cycle. This fell to
below 0.5 during further treatment. Serum creatinine
levels were slightly increased at the end of each cycle.
Patient #11: A 54-year-old man with esophageal cancer
tolerated the regimen well. His AKIRisk score rose to
higher ranges after the administration of cisplatin during
each cycle, with peak levels of 2.6 on day 2 during the
second cycle. A marginal increase in sCr was noted, but
sCr remained in the normal range. His treatment was
changed after three cycles because of cisplatin-induced
neuropathy.
Patient #12: A 57-year-old man with cancer of the hy-
popharynx was admitted to the hospital for chemother-
apy. During the first and second cycles of cisplatin his
AKIRisk score increased to 2.7 on day 3 of cycle 1. Con-
currently sCr was slightly elevated after the first 2 cycles,
but remained within normal range.
Discussion
The present report describes the dynamics and applic-
ability of a novel and rapid urine-based diagnostic
method for evaluating the risk of imminent kidney failure,
compared to serum creatinine levels. Acute kidney injury
as such is known to be a poor prognostic factor in terms
of mortality [24]. We concentrated on four settings: IRI in
the context of kidney transplantation, cardiac failure,
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severe AKI leading to end-stage renal disease, and toxin-
induced kidney injury. The cases described here indicate
that, in patients with ischemic reperfusion and toxic
injury, [IGFBP7] · [TIMP-2] (= AKIRisk) rise rapidly and
decline fast, even before polyuria becomes evident. When
the AKIRisk score remains below 8, the concomitant rise
in sCr and the stage of AKI appear to be reversible.
Conversely, patients with values above 18 and pro-
longed high-levels of [IGFBP7] · [TIMP-2] excretion
were unable to recover and needed renal replacement
therapy permanently, as noted in patients #8 and #9.
However, one 94-year-old woman with prerenal acute
kidney injury and a high AKIRisk score of 17.9 recov-
ered fully under antibiotic and hydration therapy (as
shown in Additional file 3: Figure A, patient C). Another
patient, also described in the supplement, had a peak level
of 27 shortly after surgery, which fell to 2 over the next
32 h.
Of patients with AKI and CKD, patient #4 had a pro-
longed high AKIRisk score with falling sCr levels. These
unexpected dynamics might be explained by the patient’s
stage of CKD and her previous history of intermittent
kidney replacement therapy at the intensive care unit
1 month earlier.
The course of disease seems to differ from patient to
patient. As shown by other authors as well, repair mech-
anisms might contribute to the patients’ levels of secre-
tion [16]. Kidney injury might be brief and quite simply
caused by a surgical intervention [15], as observed in pa-
tients B and D (Additional file 3: Figure A). This may re-
sult in an increase in sCr 24 to 30 h later, while peak
AKIRisk levels are observed as early as 2 h after the sur-
gical intervention. Moreover, in cadaver kidney recipi-
ents who have experienced IRI, a rise in AKIRisk levels
is seen shortly after implantation of the organ, when
urine flow starts. However, these patients experience a
rapid decline of values within just 48 h, which is not par-
alleled by polyuria. The phase of polyuria and subse-
quent recovery of kidney function occurred a little later
than the decline in AKIRisk levels. In contrast, this was
not the case when a living donor kidney was implanted,
as shown in patient A (Additional file 3: Figure A). Im-
mediately after organ implantation and urine flow, the
patient’s AKIRisk score fell to below 0.06.
With regard to toxic kidney injury due to chemother-
apy, the increase in AKIRisk levels was followed by a
marginal increase in serum creatinine. This was noted in
patient #7, whose high AKIRisk score resulted in a slight
increase in serum creatinine 72 h later. The toxic effects
either occur in a small population of nephrons or are of
such a small magnitude that they do not result in clinic-
ally measurable pathologies. However, earlier studies
have clearly shown that marginal changes in serum cre-
atinine might be related to toxic injury, which is relevant
with regard to the patient’s subsequent life span [25].
Nephrologists have claimed that renal disease might be
accompanied by minimal or no changes in serum cre-
atinine because of renal reserves and various degrees of
tubular creatinine excretion [11].
The brisk kinetics of [IGFBP7] · [TIMP-2] after tubular
cell injury during surgery or ischemic reperfusion was
clearly seen in the majority of our patients. However,
this might be different in CKD patients, especially in
those with diabetic nephropathy (patient #4). Injury
under these conditions might induce a more prolonged
cascade of cell cycle arrest, causing signaling, which in-
duces further fibrosis and vascular rarefication [17, 26].
The very brisk and rapid dynamics of these parameters
is associated with limitations in terms of method. Timely
detection of tubular cell injury might require frequent
testing, especially at the intensive care unit. Further
studies are needed to evaluate the applicability of the
test in the very complex and varying patterns of acute
kidney injury.
One of the limitations of the study and the test method
is that it is still unclear why patients responding with high
NephroCheck levels after chemotherapy do not show an
immediate rise in sCr. However, our own observations re-
garding tubular-cell-derived urinary proteins show that
the presence of subclinical tubular cell injury does not ne-
cessarily result in elevated sCr levels. One patient (#9) had
prolonged high levels and eventually went into RRT. The
secretion of [IGFBP7] · [TIMP-2] in this patient might
have been connected to his renal disease.
As the present investigation was not performed for the
purpose of test validation, no conclusions can be drawn
in regard of risk stratification. However, the time point
of NephroCheck testing is obviously crucial. Further re-
search should be focused on the various types of disease
and the corresponding AKIRisk scores.
Conclusion
Nephrocheck was tested in 69 patients, in different set-
tings of acute kidney injury. The dynamics of this test
are compared to serum creatinine in the present report.
A brisk decline in AKIRisk levels was indicative of the
restoration of kidney function to a previous stage. How-
ever, the patients’ AKIRisk dynamics varied. One limita-
tion of the study is the wide spectrum of disease entities
and comorbidities in the individual patients. Future
studies should be focused on specific disease entities.
Additional files
Additional file 1: Table A: Demographics of the four additional
patients. (XLSX 10 kb)
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Additional file 2: Description of the four additional patients as well
as table and figure legends of table A, table B, figure A, figure B.
(DOCX 18 kb)
Additional file 3: Figure A: Time course of [IGFBP7] · [TIMP-2] of the
four additional patients. (TIF 949 kb)
Additional file 4: Table B: Demographic data of the entire patient
cohort (n = 69). (XLSX 9 kb)
Additional file 5: Figure B: TIMP-2 immunofluorescence staining of
tubular cells in the urine sediment of patient #2. (TIF 6713 kb)
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